news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

cancer has always been the biggest threat to human health. fortunately, with the advancement of medicine, more and more cancer patients have the opportunity to receive accurate, systematic and effective treatment. cancer is gradually changing from a "terminal illness" to a "chronic disease", thanks to the great breakthroughs brought about by precision medicine.

we all know that tumors are caused by the loss of normal regulation of local tissue growth at the genetic level, which leads to uncontrolled and crazy cell growth. in essence, it is a genetic disease. only by accurately locating the genetic source of the disease can we prescribe the right medicine to cure the disease.

companion diagnostics are the "gps" for doctors to develop precision medical plans, accurately locating the genetic source of the disease. amoy biotech, a listed company located in xiamen, is an expert in making these "gps" and a leading company in this field. the company has been deeply engaged in companion diagnostics for precision medicine for tumors for 16 years, and has 28 products approved for marketing so far. it is a "national manufacturing single champion enterprise" recognized by the ministry of industry and information technology.

recently, another companion diagnostic product of aide biotechnology - "aide pcr-11 gene detection kit (trade name: ahuijie®)" was approved for marketing by the national medical products administration. this product uses simple, fast and clinically popular pcr technology to solve the pain point that "more" and "fast" cannot be taken into account at the same time in clinical practice. it can detect 11 target genes required for the clinical treatment of lung cancer at one time, helping doctors to quickly develop precision medicine plans.

it is reported that the product has been approved for marketing by the ministry of health, labor and welfare of japan (pmda) as early as june 2021. so far, it has been approved for 7 major companion diagnostic labels for non-small cell lung cancer and 16 related targeted drugs from 10 well-known domestic and foreign pharmaceutical companies. the companion diagnostics were included in japan's medical insurance in january 2022. in addition, the product has also passed the eu ce certification and has become a widely used lung cancer companion diagnostic product in overseas clinical practice. as the first company to realize the overseas export of "made in china" tumor companion diagnostics, amoy biotech has been repeatedly recognized in the high-threshold international market and is leading the international stage step by step.

(recommended catalog of common tumor gene tests issued by the fujian provincial health commission)

now, ahuijie® has been approved for marketing in china, and lung cancer patients in my country can finally use this internationally recognized good product, which is the result of scientific and technological innovation and the practice of new quality productivity in the field of precision medicine. it is worth mentioning that according to the documents of the fujian provincial health commission and the latest policy of medical insurance reimbursement, this product can not only perfectly cover all lung cancer genes recommended by the fujian province common tumor gene testing catalog, but also meet the scope of medical insurance reimbursement, and related targeted drugs have also been included in medical insurance. this means that in some provinces and cities in my country, lung cancer patients can enjoy medical insurance reimbursement for testing and drugs when they are treated in hospitals, achieving "double reduction", which is undoubtedly an exciting good news.

genetic testing accompanies almost the entire process of cancer diagnosis and treatment. we look forward to the development and launch of more genetic testing products and related drugs, the continuous innovation of precision medical solutions, and the continuous optimization of medical insurance reimbursement policies, so that cancer can be rapidly developed in the direction of "better treatment" and "affordable treatment". at the same time, we also expect more companies like amoy biotech to contribute to the practice of new quality productivity in their own fields.

about amoydx

aide biotech is rooted in xiamen haicang biomedicine port and was listed on the growth enterprise market in 2017. it is recognized by the industry as a leading company in tumor precision detection, a national enterprise technology center, a specialized and innovative small giant enterprise, and a national manufacturing single champion enterprise. the company has more than 70 independent patents, breaking the technology monopoly of multinational companies, and has been approved to launch a number of industry-leading innovative products. it has won the second prize of the national science and technology progress award and the silver award for chinese patents. the products cover the precise detection of major cancers. many products have not been approved for listing by competitors so far. the products have also been approved for listing in japan, south korea, and the european union and included in the medical insurance of japan and south korea, and are widely used in more than 70 countries and regions around the world. the company has reached strategic cooperation with more than 80 well-known pharmaceutical companies at home and abroad, including astrazeneca, johnson & johnson, amgen, eli lilly, merck, hengrui, beigene, and haihe, and has successfully helped accelerate the approval of a number of blockbuster targeted drugs at home and abroad, allowing "china's smart manufacturing to move towards the world" and leading the high-quality development of global tumor precision diagnosis and treatment.